Abstract

SARS-CoV-2 infection-induced aggravation of host innate immune response not only causes tissue damage and multiorgan failure in COVID-19 patients but also induces host genome damage and activates DNA damage response pathways. To test whether the compromised DNA repair capacity of individuals modulates the severity of COVID-19 infection, we analyze DNA repair gene expression in publicly available patient datasets and observe a lower level of the DNA glycosylase NEIL2 in the lungs of severely infected COVID-19 patients. This observation of lower NEIL2 levels is further validated in infected patients, hamsters and ACE2 receptor-expressing human A549 (A549-ACE2) cells. Furthermore, delivery of recombinant NEIL2 in A549-ACE2 cells shows decreased expression of proinflammatory genes and viral E-gene, as well as lowers the yield of viral progeny compared to mock-treated cells. Mechanistically, NEIL2 cooperatively binds to the 5’-UTR of SARS-CoV-2 genomic RNA to block viral protein synthesis. Collectively, these data strongly suggest that the maintenance of basal NEIL2 levels is critical for the protective response of hosts to viral infection and disease.

NEIL2, a mammalian DNA repair enzyme, has been reported to suppress infection induced inflammation. Here, the authors characterize its role in modulating the severity of SARS-CoV-2 infection.

Details

Title
The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection
Author
Tapryal, Nisha 1 ; Chakraborty, Anirban 1 ; Saha, Kaushik 2   VIAFID ORCID Logo  ; Islam, Azharul 1 ; Pan, Lang 3 ; Hosoki, Koa 4 ; Sayed, Ibrahim M. 5 ; Duran, Jason M. 6 ; Alcantara, Joshua 7   VIAFID ORCID Logo  ; Castillo, Vanessa 7 ; Tindle, Courtney 7 ; Sarker, Altaf H. 8   VIAFID ORCID Logo  ; Wakamiya, Maki 9 ; Cardenas, Victor J. 1 ; Sharma, Gulshan 1 ; Crotty Alexander, Laura E. 10   VIAFID ORCID Logo  ; Sur, Sanjiv 4 ; Sahoo, Debashis 11   VIAFID ORCID Logo  ; Ghosh, Gourisankar 12   VIAFID ORCID Logo  ; Das, Soumita 5 ; Ghosh, Pradipta 13   VIAFID ORCID Logo  ; Boldogh, Istvan 3 ; Hazra, Tapas K. 1   VIAFID ORCID Logo 

 University of Texas Medical Branch, Department of Internal Medicine, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964) 
 University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); SRM University-AP, Department of Biological Sciences, School of Engineering and Sciences, Guntur District, India (GRID:grid.473746.5) 
 University of Texas Medical Branch, Department of Microbiology and Immunology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964) 
 Immunology Allergy and Rheumatology, Baylor College of Medicine, Department of Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 University of California, Department of Pathology, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of Massachusetts-Lowell, Department of Biomedical and Nutritional Science, Lowell, USA (GRID:grid.225262.3) (ISNI:0000 0000 9620 1122) 
 UC San Diego Medical Center, Department of Internal Medicine, Division of Cardiology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 University of California San Diego, Department of Cellular and Molecular Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 Life Sciences Division, Lawrence Berkeley National Laboratory, Department of Cancer and DNA Damage Responses, Berkeley, USA (GRID:grid.184769.5) (ISNI:0000 0001 2231 4551) 
 University of Texas Medical Branch, Department of Neurology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964) 
10  University of California, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
11  University of California San Diego, Department of Pediatrics, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego, Department of Computer Science and Engineering, Jacob’s School of Engineering, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
12  University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
13  University of California San Diego, Department of Cellular and Molecular Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
Pages
8169
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2899736714
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.